Key facts
- This page summarizes Jonathan H. Kaufman's Form 4 filing for LIPELLA PHARMACEUTICALS INC. (LIPO).
- 4 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 07 Apr 2025, 19:16.
Jonathan H. Kaufman - 03 Apr 2025 Form 4 Insider Report for LIPELLA PHARMACEUTICALS INC. (LIPO)
- Reporting relationship
- President, Chief Executive Officer, Secretary, Treasurer, and Chairman of the Board of Directors, Director, 10%+ Owner
- Issuer ticker
- LIPO
- Reported as of
- 03 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Apr 2025, 19:16:11 UTC
- Prior SEC filing
- 17 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan H. Kaufman
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Jonathan H. Kaufman filed Form 4 for LIPELLA PHARMACEUTICALS INC. (LIPO) on 07 Apr 2025.
Change
- Previous filing in this sequence was filed on 17 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LIPO
transaction
Derivative
Series C Voting Convertible Preferred Stock
Other
- Transaction value
- $0
- Shares
- -536,959
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 03 Apr 2025
- Ownership
- By Self as proxy and power of attorney for Spartan and an Affiliate (each as defined below)
- Underlying class
- Common Stock
- Underlying amount
- 536,959
- Exercise price
- $1.00
- Footnotes
- F1, F2, F3
LIPO
transaction
Derivative
Common Stock Purchase Warrants
Other
- Transaction value
- $0
- Shares
- -125,833
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 03 Apr 2025
- Ownership
- By Self as proxy and power of attorney for Spartan and an Affiliate
- Underlying class
- Common Stock
- Underlying amount
- 125,833
- Exercise price
- $1.00
- Footnotes
- F1, F2
LIPO
transaction
Derivative
Common Stock Purchase Warrants
Other
- Transaction value
- $0
- Shares
- -28,924
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 03 Apr 2025
- Ownership
- By Self as proxy and power of attorney for Spartan and an Affiliate
- Underlying class
- Common Stock
- Underlying amount
- 28,924
- Exercise price
- $1.00
- Footnotes
- F1, F2
LIPO
transaction
Derivative
Common Stock Purchase Warrants
Other
- Transaction value
- $0
- Shares
- -4,060
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 03 Apr 2025
- Ownership
- By Self as proxy and power of attorney for Spartan and an Affiliate
- Underlying class
- Common Stock
- Underlying amount
- 4,060
- Exercise price
- $1.00
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Such Series C Voting Convertible Preferred Stock, par value $0.0001 per share ("Preferred Stock"), and the common stock, par value $0.0001 per share, of the issuer ("Common Stock"), issuable upon conversion of Preferred Stock ("Conversion Shares") and exercise of the Common Stock purchase warrants (the "Warrant Shares", and collectively with the Preferred Stock and Conversion Shares, "Securities") were subject to an irrevocable proxy and power of attorney, effective December 20, 2024, between the reporting person and Spartan Capital Securities, LLC ("Spartan"), pursuant to which the reporting person had voting power over all Securities held by Spartan and its Affiliates (defined under Rule 405 of the Securities Act of 1933, as amended) or any person or entity acting as a group therewith ("Proxy and POA").
Footnote F2
Upon the effectiveness of a registration statement registering the Warrant Shares and Conversion Shares as of April 3, 2025, such voting power granted to the reporting person over the Securities by Spartan and such Affiliates was terminated. Please see the Proxy and POA attached as Exhibit 24 to the Form 4 filed by the reporting person with the U.S. Securities and Exchange Commission on March 17, 2025.
Footnote F3
The conversion rights of the Preferred Stock do not expire.
SEC remarks
President, Chief Executive Officer, Secretary, Treasurer, and Chairman of the Board of Directors